NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal second quarter 2023 ended March 31, 2023 and provide a corporate update on May 11, 2023 at 4:30 PM Eastern Time.

NeuroOne® to Report Second Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on May 11

Evo sEEG electrode s used for brain mapping in epilepsy surgery

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode Performed at Mayo Clinic

EDEN PRAIRIE, Minn., May 05, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that CFO Ron McClurg will present at the Sidoti Micro-Cap Virtual Conference being held May 10-11, 2023.

NeuroOne® to Present at the Sidoti Micro-Cap Virtual Conference on May 10

Evo sEEGs complementary to Zimmer Biomet's robotic neurosurgery platform; strong market opportunity for paired technologies

NeuroOne® Announces U.S. Commercial Launch of Evo® sEEG Electrodes

Company is also developing a percutaneous (through a needle) delivery system for paddle leads EDEN PRAIRIE, Minn. , March 16, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the successful completion of an initial animal implant of its novel thin film paddle leads for spinal cord stimulation.

NeuroOne® Successfully Completes Initial Animal Implant of Novel Thin Film Paddle Lead for Spinal Cord Stimulation

EDEN PRAIRIE, Minn. , March 9, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023 in Dana Point, California.

NeuroOne®#¹⁶⁰;to Participate in the 35th Annual Roth Conference

New patent adds value to NeuroOne's growing patent portfolio in the U.S. and abroad EDEN PRAIRIE, Minn. , March 7, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces it has been awarded a patent from the United States Patent and Trademark Office relating to its novel and proprietary electrode technology.

NeuroOne® Awarded U.S. Patent Covering Novel and Proprietary Thin Film Electrode Platform

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q1 2023 Earnings Conference Call February 14, 2023 4:30 AM ET Company Participants Dave Rosa - President and CEO Ron McClurg - CFO Conference Call Participants Alex Nowak - Craig Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation First Quarter Fiscal Year 2023 Financial Results Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) Q1 2023 Earnings Call Transcript

EDEN PRAIRIE, Minn. , Feb. 14, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal first quarter 2023 ended December 31, 2022.

NeuroOne® Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn. , Feb. 9, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal first quarter 2023 ended December 31, 2022 and provide a corporate update on February 14, 2023 at 4:30 PM Eastern Time.

NeuroOne® to Report First Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on February 14

Company highlights fiscal year 2022 and subsequent achievements, catalysts for fiscal year 2023 EDEN PRAIRIE, Minn. , Jan. 30, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has issued a Winter 2023 Letter to Shareholders.

NeuroOne® Issues Letter to Shareholders

EDEN PRAIRIE, Minn. , Dec. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces financial results for the fiscal fourth quarter and full fiscal year ended September 30, 2022.

NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q4 2022 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Dave Rosa - President and Chief Executive Officer Ron McClurg - Chief Financial Officer Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Corporate Update Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) Q4 2022 Earnings Call Transcript

EDEN PRAIRIE, Minn. , Dec. 13, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, to host fiscal Fourth Quarter Corporate Update for the period ended September 30, 2022.

NeuroOne® to Host Fiscal Fourth Quarter Corporate Update

EDEN PRAIRIE, Minn. , Dec. 8, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal fourth quarter and full fiscal year ended September 30, 2022, and provide a corporate update, on December 13, 2022 at 4:30 PM Eastern Time.

NeuroOne® to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide Corporate Update on December 13

Animal study completed under the guidance of Dr. Jamie Van Gompel at the Mayo Clinic in Rochester, MN Company on track to submit OneRF 510(k) application to the FDA in the second quarter of calendar year 2023 EDEN PRAIRIE, Minn. , Dec. 6, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has successfully completed a feasibility study with its OneRF™ ablation system, a developing technology that utilizes existing implanted sEEG diagnostic electrodes for brain tissue lesioning.

NeuroOne® Successfully Completes Feasibility Study with its OneRF™ Ablation System

Company focused on manufacturing and commercialization in partnership with Zimmer Biomet EDEN PRAIRIE, Minn. , Nov. 30, 2022 /PRNewswire/ --  NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it shipped the first commercial order to Zimmer Biomet for its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

NeuroOne® Ships Initial Zimmer Biomet Order for its Evo® sEEG System for Less than 30 Day Use

Ceremony to commemorate recent FDA clearance milestone for Company's Evo® sEEG Electrode technology EDEN PRAIRIE, Minn. , Nov. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it will ring the Nasdaq closing bell today Tuesday, November 22, 2022, to commemorate its recent corporate milestone achievement for the Evo® thin film electrode platform.

NeuroOne® to Ring Nasdaq Stock Market Closing Bell on November 22

CytomX Therapeutics

Ensysce Biosciences

Nexalin Technology Inc

Taysha Gene Therapies

Biotech penny stocks to watch this week. Are they a buy now?

Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week

EDEN PRAIRIE, Minn. , Nov. 21, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces an appearance by Chief Executive Officer Dave Rosa on Fox Business Network's Mornings with Maria earlier today.

NeuroOne® CEO Dave Rosa Featured on Fox Business Network's 'Mornings with Maria'

Company focused on manufacturing ramp for commercialization in partnership with Zimmer Biomet EDEN PRAIRIE, Minn. , Oct. 25, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use

EDEN PRAIRIE, Minn. , Sept. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective September 20, 2022, the Compensation Committee of the Board of Directors approved two equity awards under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the "Inducement Plan"), as a material inducement to the individuals entering into employment with the Company.

NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q3 2022 Earnings Conference Call August 11, 2022 5:30 PM ET Company Participants Dave Rosa - President and Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Third Quarter of Fiscal Year 2022 Financial Results Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) CEO Dave Rosa on Q3 2022 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn. , Aug. 11, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter of fiscal year 2022 ended June 30, 2022.

NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Company re-submits application to gain FDA clearance for less than 30 day use EDEN PRAIRIE, Minn. , Aug. 9, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company submitted a special 510(k) to the U.S. Food and Drug Administration ("FDA") on August 8 th for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 day use.

News for NeuroOne Medical Technologies Corp Stock (NMTC)